Randomized Placebo-Controlled Trial to Determine the Biological Signature of Cannabidiol as a Treatment for Social Anxiety Disorder

Brief description of study

The purpose of this research study is to determine whether cannabidiol (CBD), a non-psychoactive part of cannabis, is an effective treatment for social anxiety disorder (SAD), and to better understand how CBD might improve SAD symptoms. After medical and psychiatric evaluations are completed, eligible participants are randomly assigned (that is, by chance) to one of two treatments lasting approximately 3 weeks: CBD or placebo. The study will last about 1-2 months and full participation includes 6 study visits as well as fMRI neuroimaging scans, a stress task, and blood tests. Eligible participants receive compensation for time completing study assessments.

Clinical Study Identifier: s22-00568

Principal Investigator: Naomi M. Simon.

Other Investigators: Matteo Malgaroli, Michele Santacatterina, Kristin L Szuhany, Benjamin Feldman, Esther Blessing.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies